HighTide Therapeutics Inc
Company Profile
Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Building D, Guangdong
Floor 9 to 10, Fubao Community, Futian District
Shenzhen-Hong Kong Science and
Technology Innovation Cooperation Zone
Shenzhen518112
CHNT: +86 75526626253
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.10 | 3.90 | -0.04% |
| CAC 40 | 7,695.19 | 47.05 | -0.61% |
| DAX 40 | 23,438.58 | 260.54 | -1.10% |
| Dow JONES (US) | 42,515.09 | 317.30 | 0.75% |
| FTSE 100 | 8,842.67 | 32.55 | -0.37% |
| HKSE | 23,980.30 | 80.69 | -0.34% |
| NASDAQ | 19,701.21 | 294.39 | 1.52% |
| Nikkei 225 | 38,536.74 | 225.41 | 0.59% |
| NZX 50 Index | 12,639.35 | 50.78 | -0.40% |
| S&P 500 | 6,033.11 | 56.14 | 0.94% |
| S&P/ASX 200 | 8,541.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,387.40 | 1.32 | -0.04% |